Rapport Therapeutics Shares Fall After CEO Comments on RAP-219 Bipolar Mania Trial
Shares of Rapport Therapeutics dropped after conference remarks on RAP-219’s bipolar mania study, weeks before the planned October readout.
/ 5 items
#RAPP↓
Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Rapport Therapeutics Lands $328M China Deal for Next-Gen Seizure Treatment RAP-219
Rapport Therapeutics partners with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China. $20M upfront + up to $308M milestones and tiered royalties for epilepsy & bipolar treatment.
Wells Fargo Gives Rapport Therapeutics an “Overweight” Rating
Wells Fargo analyst rates Rapport Therapeutics as Overweight with $43 target, citing strong Phase 2a seizure data and promising efficacy.
Rapport's RAP-219: Breakthrough for Focal Onset Seizures
RAP-219 shows amazing Phase 2a results for drug-resistant focal seizures: 77.8% seizure reduction & 24% seizure-free! This precision medicine, targeting TARPγ8, is well-tolerated & moves to Phase 3, offering new hope. Also eyed for bipolar mania & pain.